The association of telomere length with substance use disorders: a systematic review and meta‐analysis of observational studies by Navarro‐Mateu, Fernando et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/add.15312 
 
This article is protected by copyright. All rights reserved. 
 
Navarro-Mateu Fernando (Orcid ID: 0000-0002-3228-623X) 
 
 
The association of telomere length with substance use disorders: a systematic review 
and meta-analysis of observational studies. 
Authors: Fernando Navarro-Mateu1,2,3,4, Mathilde Husky5, Pedro Cayuela-Fuentes6, Francisco-
Javier Álvarez1, Agustín Roca-Vega7, María Rubio-Aparicio8, María Dolores Chirlaque2,3,9,10, 
María Luisa Cayuela11,12, Salvador Martínez13,14 and Julio Sánchez-Meca4  
 
* Corresponding author: Fernando Navarro-Mateu, MD, PhD. Unidad de Docencia, Investigación y 
Formación en Salud Mental (UDIF-SM). Servicio Murciano de Salud. c/ Lorca, nº 58. 30120-El Palmar 
(Murcia). Spain. Email: fernando.navarro@carm.es  
Authors’ information 
1 Unidad de Docencia, Investigación y Formación en Salud Mental (UDIF-SM). Servicio 
Murciano de Salud. Murcia. Spain. 
2  CIBER de Epidemiología y Salud Pública (CIBERESP). Madrid. Spain. 
3   IMIB-Arrixaca. Murcia. Spain. 
4   Departamento de Psicología Básica y Metodología. University of Murcia., Murcia. Spain. 
5  Université de Bordeaux, Laboratoire de Psychologie EA4139, Bordeaux, France. 
6  Escuela Universitaria de Enfermería de Cartagena, University of Murcia, Murcia. Spain. 
7 Biblioteca Virtual MurciaSalud. Centro Tecnológico de Información y Documentación 
Sanitaria, Servicio Murciano de Salud. Murcia. Spain. 
8  Departamento Psicología de la Salud, University of Alicante, Alicante. Spain.  
9  Servicio de Epidemiología. Consejería de Salud. Murcia. Spain.  
10 Departamento de Ciencias Sociosanitarias. University of Murcia. Spain.  
11 Grupo Telomerasa, Cáncer y Envejecimiento. Hospital Clínico Universitario Virgen de la 
Arrixaca. Murcia. Spain. 
12  CIBER de Enfermedades Raras (CIBERER). Madrid. Spain. 
13  Instituto de Neurociencias. UMH-CSIC. Alicante. Spain. 
14  CIBER de Salud Mental (CIBERSAM). Madrid. Spain. 
Email addresses: 
FNM: Fernando Navarro-Mateu. Email address: fernando.navarro@carm.es  
MH: Mathilde Husky. Email address: mathilde.husky@u-bordeaux.fr  
PCF: Pedro Cayuela-Fuentes. Email address: cayuela.pedro@gmail.com  
FJA: Francisco-Javier Álvarez. Email address: franciscoj.alvarez@carm.es  
ARV: Agustín Roca-Vega. Email address: agustin.roca@carm.es  
MRA: María Rubio-Aparicio. Email address: maria.rubio@ua.es 
MDC: María Dolores Chirlaque. Email address: mdolores.chirlaque@carm.es  
 
This article is protected by copyright. All rights reserved. 
MLC: María Luisa Cayuela. Email address: marial.cayuela@carm.es 
SM: Salvador Martínez. Email address: smartinez@umh.es  
JSM: Julio Sánchez-Meca. Email address: jsmeca@um.es  
 
Running head: Telomere length and substance use disorders. 
Word count: 3938.  
Conflict of interest declaration Dr Navarro-Mateu reports non-financial support from Otsuka 
outside the submitted work. Others coauthors declare no conflict of interest. 
 
 ABSTRACT  
Background and Aims Several recent studies have investigated the relationship between 
telomere length and substance use disorders with inconsistent results. We aimed to assess this 
association and to identify moderators of the relationship.  
Methods Systematic review and meta-analysis. Selection criteria were observational studies 
reporting telomere length in persons with a substance use disorder compared with a control 
group. Studies focused solely on nicotine addiction, employing other study designs, and non-
human studies were excluded. Study selection and data extraction were independently 
conducted by two researchers following a standardized protocol and included studies up until 
December 2019. Standardized mean differences were used as the effect size index (d; 95%CI) 
and random-effects models were used for the meta-analysis. Cochran’s Q-statistic, I2 index, 
visual inspection of the forest plot, and a 95% prediction interval were applied to verify study 
heterogeneity. Subgroup analyses and meta-regressions were conducted to explore 
heterogeneity. Small study effects were examined using the “funnel plot”, the Egger test, Duval 
and Tweedie’s trim-and-fill method, and the PET-PEESE method. The risk of bias and the 
quality of evidence were assessed.  
Results Ten studies (12 analysis units with 2,671 cases and 4,532 controls) met the selection 
criteria. An overall effect size of moderate magnitude was found (d+= -0.63; 95%CI: -1.00 and 
-0.26; p=.0008). A potential small study effect was detected, as well as large heterogeneity 
between studies (Q-statistic p<.001, I2=97.3%). Selection of controls, reporting laboratory 
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quality control procedures and total sample size significantly affected the effect size. The 
quality of the evidence was very low, based on risk of bias analysis and the GRADE system. 
 Conclusions People with substance use disorders appear to have shorter telomere length than 
controls; however, this finding should be interpreted with caution due to the poor quality of the 
evidence. 
 
Systematic review registration: PROSPERO registration number CRD42019119785. 
KEYWORDS Telomere length; Substance Use Disorders; Cellular aging; Alcohol; Meta-
analysis; Systematic Review 
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INTRODUCTION  
Telomeres are repetitive noncoding DNA protein structures consisting of nucleotide 
sequences of tandem TTAGGG repeats at the end of chromosomes in association with a protein 
complex. These structures are essential for maintaining genome stability (1) and for ensuring 
the regulation of gene expression (2). Telomere length (TL) varies throughout  the lifespan and 
is considered as a marker of cellular aging (3–5). Telomere attrition has been associated with 
increased all-cause mortality risk (6) and in particular, with increased morbidity of various age-
related diseases (7–12). Results of recent meta-analyses suggest that TL might be associated 
with a variety of mental disorders (13–19). However, a non-systematic review has highlighted 
inconsistencies of the published results regarding the association between substance use 
disorders (SUDs) and telomere length (20). 
SUDs constitute one of the major public health issues around the world (21,22), are 
major contributors to burden of disease (23) with greater risk of disability (24) and mortality 
(25). Early detection of addiction is considered crucial for preventing premature morbidity and 
mortality (26). Comorbidity is highly prevalent between SUDs and both psychiatric disorders 
(27) and medical conditions (28). To the best of our knowledge, no systematic review or meta-
analysis examining the association of telomere length with SUD related to any substance other 
than tobacco (29) was ever conducted.  
The aims of the present study were i) to determine whether persons with SUDs have 
shorter telomere lengths as compared to healthy controls, ii) to explore potential differential 
effects with regard to diverse substances, iii) to identify potential moderators of the telomere 
length effect. The research questions were: i) Do people with SUDs have shorter telomere 
lengths compared with healthy controls?; ii) Are there differences in the association of TL with 
SUD as a function of the type of substance that is misused?; and iii) If heterogeneity is 
confirmed, what are the factors implicated?. 
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METHODS 
Protocol and registration 
The protocol of this investigation was registered with the International Prospective 
Register of Systematic Reviews (PROSPERO  2019 CRD42019119785, 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=119785) and published 
previously (30). We wrote this report using the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA guidelines) (31) and the proposal for reporting Meta-
analysis of Observational Studies in Epidemiology (MOOSE) (32). 
Study eligibility criteria 
Inclusion criteria were as follows: (a) Populations: Adult with SUDs, except if the 
disorder is exclusively based on nicotine addiction, and healthy controls; (b) Exposure: SUD 
covered alcohol, illicit drugs including cocaine, opiates, or other substances (e.g. marijuana 
and amphetamine, among others). Case status had to be defined as having any substance use 
disorder identified through a clinical interview or using established standard diagnostic 
instruments including, but not limited to, the Structured Clinical Interview for DSM-IV 
(SCID), Computerized National Institute of Mental Health Diagnostic Interview Schedule 
(CDISIV), the Composite International Diagnostic Interview (CIDI) or any other diagnostic 
instrument based on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, 
or; (c) Control group: adults with no SUD diagnosis (e.g. from the general population, the 
community, unexposed out-patient, or hospital-based controls); (d) Outcomes: telomere length 
measurements with a detailed description of both the methods of measurement and the isolated 
tissue that was used; and (e) Study designs: observational studies (case-control, cohort, cross-
sectional, longitudinal designs). Exclusion criteria were: systematic or narrative reviews, meta-
analyses, studies with non-human samples or other designs including reviews, case-only 
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studies, family-based designs, population-based studies with healthy subjects only, as well as 
studies focused on tobacco smoking.  
Information sources and search strategy 
Comprehensive electronic searches were conducted to identify studies indexed in 
PubMed/MEDLINE, EMBASE, Psychlit/PsychINFO, and Web of Science databases (Web of 
Knowledge) from inception until December 2019. The search was performed by a librarian 
with expertise in systematic reviews. The following search terms were used for SUDs: “drug, 
substance, addiction, alcohol*, heroin, cocaine, opium, opioid, methamphetamine, morphine” 
and for telomeres: Telomeres, telomerase, and telo*” (see Table S1). The references cited in 
each study included in this initial selection and in review articles were then manually searched 
to identify other potentially eligible studies. To minimize potential publication bias, both 
published and unpublished papers were eligible for inclusion. In order to identify unpublished 
studies, e-mails were sent to the corresponding authors of the selected studies to enquire about 
any potential study that met eligibility criteria. In the search strategy, no restrictions were 
placed on time period, sample size, ethnicity or language of publication.  
Data extraction  
The following data were extracted from each study following the previously defined 
protocol: i) identification data of the study (author(s), journal, language, and year of 
publication); ii) methods (study design, sample sizes for both cases and controls, diagnostic 
tools for the determination of case status, definition of case status, variables adjusted for in the 
analyses, attrition for cases and controls and differential attrition); iii) risk of bias assessment 
(described in greater detail below); iv) sample characteristics for both cases and controls 
separately (gender ratio, mean age and standard deviation (SD), ethnic background, education 
level, type of substance used in SUD cases, duration of SUD in cases, presence of comorbid 
mental disorders or medical conditions in cases, smoking status, exposure to childhood 
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adversities and other stressful life events); v) telomere-related information (telomere length, 
tissue source and telomere measurement method), and (vi) extrinsic characteristics (relevant 
ethical approval, conflict of interest disclosure and funding source).  
If an article reported two or more studies with independent samples, then each 
independent study was included as an analysis unit in the meta-analysis. When essential data 
were unavailable in the original studies, authors of the respective papers were contacted and 
asked to provide additional data. Two reviewers independently determined eligibility and 
extracted data from included studies. Disagreements were resolved by consensus or reached 
with the involvement of a third reviewer. To assess the reliability of the data extraction process, 
in terms of inter-rater agreement, kappa coefficients were calculated between the two 
reviewers. 
Risk of bias assessment 
The risk of bias of each included study was assessed using the Newcastle-Ottawa Scale 
(NOS; (33)). Discrepancies in the quality assessment of each study were resolved by consensus. 
A Total Quality Score (TQS) of each individual study was calculated by adding all the stars 
(range: 0-9, with a higher score indicating higher overall quality). Studies were not weighted 
by the TQS and the influence on the effect size of each item was individually assessed (34). In 
addition to the NOS, several study characteristics (e.g. if a blind assay assessment and genetic 
quality procedures were reported, as well as the evaluation of psychiatric or physical 
comorbidities or the exposure to childhood adversities or other stressful events) were extracted 
to analyze their potential risk of bias on the effect sizes.  
Effect size index 
For each study, means and SDs on TL measured in T/S ratio scale were extracted. These 
data were converted into Hedges’ standardized mean difference (d) as effect size index. The d 
index was calculated as the mean difference in telomere length between the SUD and control 
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groups, divided by the pooled standard deviation of the two groups (35). Negative ds 
represented a shorter telomere length for the SUD group as compared to the control group. By 
convention, d indices of 0.20, 0.50, and 0.80 (in absolute value) were considered of small, 
moderate, and large magnitude, respectively (36). For each d index, a 95% confidence interval 
(95% CI) was calculated. In this meta-analysis unadjusted effect sizes (ds) were used. As 
described in the Results section, the reason for not analyzing adjusted effect sizes was that the 
majority of the studies did not report the statistical information needed to calculate an adjusted 
effect size using the same metric used for the unadjusted standardized mean difference (i.e., 
adjusted means and SDs to calculate adjusted standardized mean differences). The potential 
influence of confounding factors was assessed as described below. Table S2 describes how the 
data were extracted from the studies and d indices were calculated.   
Statistical analyses 
Random-effects models were used to analyze the TL-SUD association due to an 
expectation of a high level of heterogeneity among the studies. An average effect size and a 
95% CI was calculated with the improved method proposed by Hartung and Knapp (37–39). 
In addition, a 95% prediction interval around the average effect size was calculated in order to 
provide a prediction of the expected true effects if a new study is conducted (40).  
To estimate heterogeneity between studies, the Cochran’s Q-statistic, the I2 index, and 
visual inspection of the forest plots were used. In addition, heterogeneity was assessed with the 
between-studies variance and corresponding 95% confidence interval (41). Finally, the 
estimated proportion (and 95% confidence interval) of true effect sizes exceeding a meaningful 
threshold was calculated, considering -0.20 as the threshold effect size for these calculations in 
terms of standardized mean difference (42).  
In cases of moderate-to-large heterogeneity (I2> 25%), we attempted to identify 
possible explanations using subgroup analyses and meta-regressions based on the most 
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important characteristics of the studies, including items used to evaluate the risk of bias. The 
analyses of moderating variables was individually assessed (32) and were accomplished by 
assuming a mixed-effects model (43). The improved F statistic was applied for testing the 
statistical significance of each moderator (44). To estimate the proportion of variance 
accounted for by the moderator, an R2 index was calculated (45). Simple and multiple mixed-
effects meta-regression was applied to analyze the influence of the following moderators on 
the effect sizes: publication year, mean and SD of the age (total, case, and control samples), 
mean age difference, SD of age difference, percent male (total, case, and control sample), 
percent male difference, sample size, and NOS total quality score. 
The presence of small study effects was examined using the “funnel plot” method in 
combination with Duval and Tweedie’s trim-and-fill method (46), the Egger test (47), and the 
Precision-Effect Test–Precision-Effect Estimate with Standard Error (PET-PEESE) method 
(48). An additional sensitivity analysis was performed with the ‘leave-one-out’ method, by 
systematically removing each study and recalculating the overall results. All statistical analyses 
were conducted using the metafor program in R (49), except for the PET-PEESE method that 
was conducted with SPSS macros (48). The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence 
(50). 
RESULTS 
Study eligibility and data collection 
We first identified a total of 1,173 studies. After duplicates were removed, titles and 
abstracts of 701 studies were screened for eligibility and 558 were excluded. A total of 143 
full-text studies were assessed for eligibility and 133 of them were excluded (see flow chart in 
Figure 1 and individual reasons for exclusion in Table S3). Inter-rater agreement in the 
selection process was reached in 96% of the studies. Finally, 10 studies (12 analysis units) were 
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selected for the meta-analysis. Although efforts to identify unpublished studies were made, all 
of the studies included in this meta-analysis were published articles. The main characteristics 
of these studies are summarized in Tables 1 and 2. The median (SD) of the Cohen’s kappa 
inter-rater agreement coefficient was 0.70 (0.24) and ranged from 0.16 to 1.00. 
 The 10 eligible studies included 7,203 participants (2,671 cases and 4,532 controls). As 
shown in Table 1, all studies applied a case-control design. The most represented countries 
were the U.S. with 3 studies (51–53) and Japan with 2 studies (54,55). Case samples presented 
mean ages ranging between 26.2 and 74.5 years old (Mean= 47.4), whereas control samples 
ranged from 33.3 to 75.1 (Mean= 55.1). Three studies included men only (55–57) and one 
study with two analysis units included women only (58). Related to the type of substance used, 
five studies investigated alcohol (52–55,57), one alcohol and cocaine (51), one cocaine (58), 
one tobacco and marijuana (56), one a mixture of cocaine, heroin, methamphetamine and 
morphine (59), and one study did not describe the substances consumed by those diagnosed 
with SUD (60). 
 Adjusted effect sizes were not calculated due to the majority of the studies did not report 
the statistical data needed to obtain adjusted standardized mean differences (51-53,58-60). In 
addition, in one study this information was reported (57), but in terms of geometric means and 
not as arithmetic means, and two studies did not apply adjusted analyses (54,56). Only one 
study (55) reported statistical data needed to calculate an adjusted standardized mean 
difference, with a value of dadj = -1.81 (95%CI = -2.10 and -1.52), which was very similar to 
the unadjusted d index: d = -1.89 (95%CI = -2.18 and -1.59). As shown in Table 3, the variables 
most frequently used to adjust the SUD-TL association were the age, sex, and smoking status. 
The results of the adjusted statistical analyses reported in the studies (multiple linear regression 
models in most cases) are described in Table S3. Therefore, meta-analytic calculations were 
based on unadjusted effect sizes. 
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Average effect size and heterogeneity 
A forest plot of the d indices comparing average telomere length of SUD and control 
samples is presented in Figure 2. With one exception (60), every study exhibited shortened 
telomere length in SUD samples in comparison with controls, with eight studies reaching 
statistical significance (52,54–60). A overall effect size of moderate magnitude was found (d+ 
= -0.63; 95%CI: -1.00 and -0.26; p = .0008). The 95% prediction interval (-2.06 to 0.80) was 
wide, indicating that the expected effect size in a new study could exhibit a wide range of true 
effect sizes, both of negative or positive sign. It was estimated, taking into account the overall 
effect size and the between-studies variance, that about 75.5% (95%CI: 54.6%, 96.4%) of true 
effect sizes exceeded the threshold for a scientifically meaningful size of d = -0.20. In addition, 
taking d = 0.20 as a threshold in the inverse direction, this method estimated that only 9.2% of 
true effect sizes exceeded that threshold (95%CI: 0%, 23%). As a sensitivity analysis, the 
‘leave-one-out’ method was applied, finding three studies whose exclusion led to a change 
larger than 10% in the overall effect size (d-1 values = -0.56 (56); -0.50 (55)), and -0.72 (60)), 
but in all cases the adjusted overall effect size was statistically significant and of moderate 
magnitude (d > |0.50|).  
 The Q-statistic to assess heterogeneity among the effect sizes was statistically 
significant [Q(11) = 256.56, p<.001], and the I2 index was of large magnitude (I2 = 97.3%), as 
well as the between-studies variance (2 = 0.39; 95%CI: 0.04, 0.74). Taken together, these 
findings revealed the existence of large heterogeneity between studies.  
Small study effect analyses 
To assess whether small study effects were affecting to the meta-analytic results, a 
funnel plot was constructed as reported in Figure 3. The existence of asymmetry in the funnel 
plot was corroborated with the Egger test, that reached statistical significance [t(10) = -1.93, 
p=.082]. The trim-and-fill method to symmetrize the funnel plot did not add to the effect size. 
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However, when the PET-PEESE method was applied, an estimate of the overall effect size 
adjusted by small study effects was of practically null magnitude (dPET = 0.05; 95%CI: -0.46, 
0.56).  
Risk of bias analyses 
The methodological quality of the studies was assessed with the Newcastle-Ottawa 
Scale (NOS), together with several additional items not included in NOS (see Table 3 and 
Figure 4). According to the GRADE system (50), there is very low quality evidence that people 
with SUDs have shorter TL (see Table S4, based on Cochrane’s template for assessing the 
GRADE criteria (61)). 
The potential relationship between each item of NOS and the effect sizes was assessed 
by means of subgroup analyses (see Table 4). There was some evidence for the effect size 
varying by the selection of controls (p = .016; R2 = .43). Studies that selected controls from a 
hospitalized population or with no description of the selection process exhibited a slightly 
higher but non-statistically significant average effect size as compared to those with 
community controls (d+ = -0.94 vs. -0.07). Table 4 presents the results of subgroup analyses 
for three additional methodological characteristics. Of these analyses, the only one that 
exhibited a relevant association with the effect sizes was whether the study reported quality 
control procedures in genotyping methods (p = .028; R2 = .37), such that a lower average effect 
size was found when quality control methods were applied than when they were not reported 
(d+ = -0.50 vs. -1.88). However, this result must be interpreted cautiously because only one 
study did not report quality control methods. 
Types of substances related to SUD and telomere length 
Studies were classified in three categories as a function of the type of substance misuse: 
alcohol, other substances (mainly cocaine), and alcohol plus cocaine. Table 5 presents the 
results of comparing the average effect sizes for these three categories. No relevant differences 
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were found between the three types of substance (p = .788; R2 = 0). An additional analysis 
consisted of defining three dichotomous variables to categorize studies included consumers of 
alcohol, cocaine, and other substances, with codes 0 (No consumers of that substance) and 1 
(consumers). Then, a multiple meta-regression analysis was applied with these three 
moderators and the effect sizes as the dependent variable. There was no evidence of a 
relationship between the type of substance and the effect sizes (F(3, 7) = 0.47, p = .715, R2 = 
0). 
Study techniques of telomere length measurement and SUD determination 
SUD status was assessed by clinical interview or through self-reported instruments. As 
shown in Table 5, no relevant differences were found between the two methods of SUD 
assessment (p = .280, R2 = .02), although the magnitude of the difference in TL between SUD 
and controls was larger when cases were assessed by clinical interview (d+ = -0.73 vs -0.18). 
A smaller effect size was found when TL was measured using qPCR (quantitative polymerase 
chain reaction) method (d+ = -0.55 vs. -0.87), although not reaching statistical significance (p 
= .482, R2 = 0). Differences in source tissue used in the biological samples to measure TL did 
not exhibit a relevant association with the effect sizes (p = .953, R2 = 0).   
Analysis of additional moderating variables 
Subgroup analyses (ANOVA) were conducted to investigate the potential relationships 
between clinical, socio-demographical, and contextual characteristics and the effect sizes 
(Table 5). Neither the presence of psychiatric comorbidity (p = .415, R2 = 0), medical 
comorbidity (p = .660, R2 = 0), childhood trauma (p = .771, R2 = 0), or exposure to other 
stressful events (p = .917, R2 = 0) exhibited a relevant relationship with the effect sizes. 
Ethnicity of the sample (p = .788, R2 = 0), country of residence (p = .114, R2 = .61) or continent 
(p = .357, R2 = .09) where the study was conducted, or funding type (p = .196, R2 = .08) did 
not seem to affect the TL-SUD association either.   
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 Meta-regressions were applied to assess the influence of unbalanced distribution of 
several socio-demographic moderators on the TL-SUD association. As shown in Table 6, none 
of them reached a relevant association with the effect sizes: mean age and SD of the samples 
(total, cases, and controls), percent males, or study publication year, all of them exhibiting 
percentages of variance accounted for lower than 10%. However, the total sample size of the 
studies exhibited a strong relationship with the effect sizes, with 54% of variance accounted 
for (p = .007; R2 = .54; see Table 6). Figure S1 presents a scatter plot of how sample size 
affected the TL-SUD association. In particular, studies with small sample sizes exhibited 
stronger TL-SUD associations than studies with larger sample sizes. In other words, studies 
with small sample sizes found that SUD samples presented shortened TL in a larger magnitude 
than studies with large sample sizes. This result was coherent with the result of the Egger test 
above described. 
DISCUSSION 
To the best of our knowledge, this systematic review and meta-analysis is the first to 
systematically assess the TL-SUD association. The main result of a total of 12 analysis units 
suggests that people diagnosed with a SUD have a shorter TL as compared to controls. This 
finding is consistent with other recent meta-analyses suggesting that a shorter TL is associated 
with i) other mental disorders (19), such as depression (13,14), post-traumatic stress disorder 
(17), anxiety (62), and schizophrenia (15,18); ii) cigarette smoking (29), and ii) with other 
chronic age-related diseases, such as metabolic syndrome (7), diabetes mellitus (8), 
hypertension (9), cardiometabolic outcomes (10) and cardiovascular disease (11), and 
Alzheimer’s disease (12).  
Several strengths of our study should be highlighted. First, data on several potential 
moderating factors (e.g., childhood adversities, exposure to other stressful events, and 
psychiatric and physical comorbidities) was evaluated. Second, quality assessment was 
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implemented (63) using the Ottawa-Newcastle scale (33) and, although a TQS was calculated, 
each item was assessed individually in their influence on the magnitude of the effect (32). 
Third, we have evaluated risk of bias (63) and applied GRADE criteria to assess the quality of 
evidence (50). Finally, we have used PRISMA (31) and MOOSE checklist when writing this 
report (32), the protocol was registered in PROSPERO and has recently been published (30). 
Nevertheless, some limitations deserve careful consideration. At the study level these 
were: firstly, some difficulties to extract some characteristics from the studies due to 
incomplete reporting and a very low quality of evidence based on GRADE criteria (50). The 
Strengthening the REporting of Genetic Association studies (STREGA) Statement was 
published in 2009 (64) as an extension of the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) (65) and was specifically designed to enhance the 
transparency of the reports of genetic association studies based on observational designs. While 
all ten studies were published afterwards, none of them has followed these international 
recommendations. Secondly, the scarce number of included studies limited the ability to 
identify potential moderators of the association. In our attempts to explain the large 
heterogeneity observed, only two methodological characteristics were identified as moderators 
of the TL-SUD association. However, other factors have been previously described (e.g. 
childhood adversities (66), exposure to other stressful events (67), cigarette smoking (29), 
physical (7–12) and psychiatric comorbidities (13–19)). Moreover, concerns about the impact 
of different measurement techniques and variability in several critical methodological steps in 
measuring TL which may vary between cases and controls, such as sample type selection, 
protocol of sample collection, storage, processing issues, the lapse of time between sample 
collection and analyses, and assay procedures among others, have been recently published (68–
70). As a consequence, in an effort to improve the quality of telomere length research, a 
checklist of the minimum critical information necessary to enhance reproducibility between 
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laboratories, reliability and methodological rigor has been proposed (70). Thirdly, small study 
effect is suggested by our analyses, such that the most precise studies (i.e., with large sample 
sizes) were those that exhibited a very weak TL-SUD association, whereas studies with small 
sample sizes were those that obtained the largest TL-SUD associations. And fourthly, all were 
case-control studies except two studies (with three analysis units) that were cohorts in design 
but used a nested case-control analysis (53,71) with TL measured at a single point in time. Only 
one of the latter, The Heart and Soul Study described in (53), measured TL in a prospective 
manner, although the median absolute change in TL was not significant between alcohol 
consumers and abstainers after 5-year follow-up.  
At the review level, the analyses were based on unadjusted effect estimates. Using 
unadjusted effect estimates in place of adjusted estimates can lead to biased estimates of meta-
analytic parameters, such that the results must interpreted with caution. Another limitation was 
that the scarcity of studies limited subgroup or stratified analyses of individual substances. In 
addition, the results of the analyses must be interpreted with caution due to the large number 
of moderating variables analyzed and the small number of studies meta-analyzed. 
Finally, the causal nature of the association between SUDs and TL needs to be 
interpreted with caution due to other potential explanations and limitations of current research 
on this topic. A plausible mechanism is that consumption of illicit drugs might misbalance the 
equilibrium of telomere addition by telomerase, and telomere attrition due to DNA end 
replication and other factors, e.g. stressful experiences elevating oxidative stress (72,73). 
However, this traditional causal explanation of the association of a shorter TL and SUDs has 
recently been questioned (74). Telomeres are specialized structures and their complex 
functionality still needs to be well-understood, as they cannot be considered as a passive marker 
of aging, but also as essential for genome stability and its protection as well as implicated in 
its expression (1,2).  
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Future research should improve several aspects in designing and reporting studies (e.g. 
state in the method section that the TL measurements were assessed blind to the condition of 
participants and to warrant that controls pertain to the same population than cases). 
Longitudinal studies are needed to establish a temporal relationship between TL and SUDs and 
to contribute to the clarification of the nature and direction of the relationship. High-quality 
prospective studies with larger samples will contribute to ascertain the complex nature of the 
relationship between shortened TL in SUDs. Finally, relevant statistical information is very 
frequently missing in the studies; in particular, adjusted means and SDs. Studies should report 
adjusted effect estimates to improve the interpretability of their results. 
In summary, we have demonstrated that a shortened TL is associated to SUDs. Though 
noteworthy, caution should be kept in mind when interpreting these results as several 
methodological issues may alternatively explain these findings. If confirmed, TL is a promising 
marker of accelerated biological ageing in people with SUDs, a potential biomarker for 
prevention of premature morbidity and mortality and as a viable predictor of different 
pharmacological (75–77) and non-pharmacological (78,79) interventions.  
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Table 1: Main characteristics of included studies 
 
 
First author, year 







Country Study design N  Male
s  
N (%) 
















Alcohol DSM-IV Shorter TL in the oesophagial epithelium of cases. 




Alcohol & smoking DSM-IV-TR Shorter TL in alcohol abusers compared to controls 
Savolainen, 2012 Finland 
Nested Case-





Discharge Register (ICD-9 
and 10 and DSM-III-R 
classification systems) 
Participants hospitalized for any mental or 
substance use disorders had longer TL than non-
hospitalized controls. 












protocols not described 
Drug abusers exhibited significantly shorter TLs 
than controls. 












Not described (#)  
 
TL was shorter in marijuana smokers group than in 
smokers or non-smokers groups. 
Levandowski, 
2016 





Clinical interview and 
semi-structured clinical 
interview following DMS-
IV criteria, CSSA, ASI-6 
 
TL is shorter in Crack with/without early life stress 
than in controls. 




Alcohol & Cocaine 
SCID-IV, ASI, KMSK 
 
No significant TL differences in comorbid cocaine 
and alcohol use disorder. 






Screening Test & DSM IV 
criteria 
 
TL was almost 50% shorter in patients with alcohol 
dependence (AD) compared to controls. 




Alcohol SCID, AUDIT, ADS 
TL is shorter in participants with alcohol use 
disorders compared to healthy controls. 
Dixit, 2019 (&) (A) USA 
Nested Case-





Alcohol AUDIT-C No association between TL and Alcohol consumers 
(B) USA 
Nested Case-





Alcohol Self reported No association between TL and Alcohol consumers 
(†) Note: SUD: Substance Use Disorder; AUDIT: Alcohol Use Disorders Identification Test; ICD: International Statistical Classification of Diseases and Related Health Problems; DSM: Diagnostic and Statistical Manual of Mental 
Disorders; CSSA: Cocaine Selective Severity Assessment; ASI-6: Addiction Severity Index version 6; SCID: Structured Clinical Interview for DSM-IV; ASI: Addiction Severity Index; KMSK: Kreek-McHugh-Schluger-Kellogg scale; ADS: 
Alcohol Dependence Scale; TL: Telomere length 
(&)  Dixit et al (2019) describes results of two other independent studies: (A) The Heart and Soul Study and (B) The Cardiovascular Health Study (B).  
(‡) Only 5-year follow-up measurement of telomere length in cohorts was included in the analyses. 
(#) Most of participants were recruited from a hospital. It was confirmed by measurement of delta-9-tetrahydrocannabinol (THC) in urine samples. 
(ᶲ) NS: Non-smokers; S: Smokers. 
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Genetic quality  
control description 
Mean SD  Mean SD 













NR Yes Control for variations in sample preparation.  
Pavanello, 2011 0,45 0.12 
 
1.06 0.82 T/S ratio 
Multiplex real-time 
qPCR 
Leukocytes Yes Yes 
All samples run in triplicate and the average of 
the three T/S ratio measurements was used. 
Repetition of the assay for 20 samples in two 
different ways. 
Savolainen, 2012 NR NR 
 
NR NR T/S ratio Real-time qPCR Leukocytes NR Yes 
Triplicates with amplification curve standard 
deviations above 0,5 at the threshold level were 
omitted.  
 
Yang, 2013 0,78 0,18 
 
0,84 0,21 T/S ratio qPCR Leukocytes NR Yes 
All samples were run in duplicate and evaluated 
correlation. Samples with a CV>2% were 
excluded and re-run. To test the reproducibility 
of the assay, multivariate samples were 
randomly chosen and run again.  
Mohamed 2016           0,61 0,09 
 
0,77 0,11 T/S ratio qPCR Leukocytes NR Yes 
In duplicate 10 ml reaction within the same 
plate and calibrator genomic DNA in each run of 
the samples. 
Levandowski, 2016    (A) 1,33 0,16 
 
1,5 0,42 T/S ratio qPCR 
Peripheral 
blood 
NR Yes Prior to the experiment, primer sets were tested 
thoroughly to determine reaction efficiency, 
specificity, and the absence of primer-dimers. (B) 1,19 0,21 
 




Tannous, 2019 0,93  0.34  1,13 0.70 T/S ratio PCR Leukocytes NR Yes DNA samples run in duplicate 
Yamaki, 2019 1,49 (†) 0.626 
 




Leukocytes NR NR - 
Martins, 2019 1,06 0,00 
 







Reactions were pipetted in triplicate for the 
standard curves and in duplicate for the other 
samples. In all reactions, a negative control 
without cDNA template (NTC) was tested. 
Dixit, 2019                 (A) 0,83 (†) 0.149 
 
0,84(†) 0.145 kpb (†) qPCR  Leukocytes NR Yes 
T/S ratio measured in duplicate and the  
averaged was used for each participant. 
(B) 1,26 (†) 0.249 
 
1,27(†) 0.261 kbp (†) 
Southern blot 
analysis of terminal 
restriction fragment 
lengths 
Leukocytez Yes Yes 
Telomere measurements were performed in 
duplicate 
Note: kbp; kilobase pairs; qPCR: quantitative Polymerasa Chain Reaction; Q-FISH: Quantitative Fluorescence In Situ Hybridazation;  NR, not reported 
(†) Base pairs (bp) were transformed to T/S ratio using the formula: bp = 3274 + 2413*(T/S) (Dixit et al, 2019)
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Table 3: Quality characteristics of included studies 
 NEW OTAWA-CASTLE SCALE for case-control studies     
 









 Control for … 


















































Age Sex Smoking 
Other covariates 
controlled 




- - - 
 
1/9 
No No No No 
 
No No No - 
Pavanello, 
2011 












BMI, vegetable intake, 
















Diabetes mellitus, BMI, 
alcohol consumption and 
coronary  heart disease. 













assessment indicated that 
all of them were free of 
serious illness (infectious 
disease, cardiovascular 
diseases, mental 
disorders and cancer). 
Mohamed 
2016 
























No BMI and education level. 
Tannous, 
2019 




-  - 5/9 No No No No 
 Yes 
(C) 
No No Education. 























BMI, years of education, 
and African ancestry,. 
 











Race, BMI, waist-hip 
ratio, number of pack 
years & a group of 
medical conditions (†) 
and inflammatory 
markers and omega-3 
fatty acid levels. 




-  - 
5/9 






Note: BDI: Beck Depression Inventory; MHI: Mental Health Index; VS: Vitality Scale; BMI: body mass index; CTQ: Childhood Trauma Questionnaire; ELS: Early Life Stress Questionnaire; NR, not reported  
(†) Medical conditions: diabetes, hypertension, coronary artery disease, prior myocardial infarction, heart failure, prior stroke and liver disease. (*) The statistical analyses applied in each study are described in Supplementary 
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Table 4. Results of the subgroup analyses for the Newcastle-Ottawa Scale (NOS)a and 









95% CI  
ANOVA results dL        dU 
NOS-S1) Case definition       
   No 








-1.32   0.004 
-1.18   -0.03 
F(1, 10) = 0.02, p = .896 
R2 = 0      QW(10) = 246.71, p < .001 
NOS-S2) Representativeness 
of cases 
     
   No 







-1.12   -0.31 
-0.99   1.64 
F(1, 10) = 2.84, p = .123 
R2 = .14     QW(10) = 239.53, p < .001 
NOS-S3) Selection of 
controls 
     
   No 







-1.34   -0.53 
-0.60   0.46 
F(1, 10) = 8.31, p = .016 
R2 = .43     QW(10) = 152.54, p < .001 
NOS-S4) Definition of 
controls 
     
   No 







-2.27   0.90 
-1.08   -0.17 
F(1, 10) = 0.01, p = .933 
R2 = 0      QW(10) = 254.98, p < .001 
NOS-C1) Comparability      
   No 







-2.27   0.90 
-1.08   -0.17 
F(1, 10) = 0.01 p = .933 
R2 = 0      QW(10) = 254.98, p < .001 
NOS-E1) Ascertainment of 
exposure 
     
   No 







-0.97   -0.14 
-2.91   -0.05 
F(1, 10) = 1.91, p = .196 
R2 = .08    QW(10) = 234.82, p < .001 
NOS-E2) Same method of 
ascertainment 
     
   No 







-1.79   -0.14 
-0.99   -0.04 
F(1, 10) = 1.09, p = .321 
R2 = .01    QW(10) = 233.99, p < .001 
Controls without SUD?b      
   No 










-1.36   0.15 
-1.17   -0.11 
 
F(1,10) = 0.01, p = .925 
R2 = 0      QW(10) = 228.51, p < .001 
Blinded assessors?      
   Not reported 










-1.13   -0.18 
-1.54   0.51 
 
F(1, 10) = 0.08, p = .785 
R2 = 0      QW(10) = 249.02, p < .001 
Genotyping quality controlc      
   No 








-3.04   -0.73 
-0.86   -0.15 
F(1, 10) = 6.54, p = .028 
R2 = .37     QW(10) = 145.34, p < .001 
N = total sample size. k = number of studies. d+ = average effect size. dL and dU = lower and upper confidence limits for d+. F = F-statistic for testing the 
significance of the moderator. R2 = proportion of variance accounted for by the moderator. QW = statistic for testing the model misspecification. 
a NOS-E3: No missing data or similar attrition for cases and controls. This last item was not analysed because no study fulfilled it.  
b Controls were assessed for absence of SUD with a validated instrument. 
 c Reporting of quality control procedures in genotyping methods. 
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95%  CI  
ANOVA results dL        dU 
Substantive variables      
Type of substance:      
   Alcohol 
   Other 










-1.28   -0.08 
-1.62   -0.10 
-1.93   1.22 
F(2, 8) = 0.25, p = .788     
R2 = 0        QW(8) = 235.87, p < .001 
SUD measurement:      
   Clinical interview 







-1.18   -0.27 
-1.14   0.78 
F(1, 10) = 1.30, p = .280 
R2 = .02    QW(10) = 213.34, p < .001 
Telomere measurement:      
   qPCR 







-1.04   -0.06 
-1.72   -0.02 
F(1, 10) = 0.53, p = .482 
R2 = 0      QW(10) = 250.87, p < .001 
Source tissue:      
   Leukocytes 
   Other blood samples 










-1.15   -0.03 
-1.67   0.20 
-2.37   0.99 
F(2, 9) = 0.05, p = .953 
R2 = 0      QW(9) = 242.02, p < .001 
Psychiatric comorbidity?:      
   Not reported 
   Excluded 










-1.26   -0.07 
-1.60   -0.12 
-1.11   0.91 
F(2, 9) = 0.97, p = .415 
R2 = 0     QW(9) = 250.86, p < .001 
Physical comorbidity?:      
   Not reported 
   Excluded 










-1.51   0.26 
-1.53   -0.13 
-1.16   0.35 
F(2, 9) = 0.43, p = .660 
R2 = 0     QW(9) = 194.84, p < .001 
Child trauma      
   Not reported 







-1.09   -0.10 
-1.60   0.14 
F(1, 10) = 0.09, p = .771 
R2 = 0     QW(10) = 243.98, p < .001 
Other stressful exposures?:      
   Not reported 







-1.15   -0.13 
-1.44   0.25 
F(1, 10) = 0.01, p = .917 
R2 = 0     QW(10) = 229.07, p < .001 
Contextual variables      
Ethnicity:      
   Caucasian 
   Asian 
   Arabic 













-1.42   0.74 
-1.87   -0.06 
-1.00   0.54 
-3.10   0.14 
F(2, 8) = 0.25, p = .788 
R2 = 0    QW(8) = 235.87, p < .001 
 
Country:      
   Brazil 
   China 
   Egypt 
   Finland 
   Italy  
   Japan 






















-1.74   -0.002 
-1.35   0.73 
-2.70   -0.26 
-0.78   1.43 
-2.04   0.08 
-2.21   -0.54 
-0.77   0.37 
F(6, 5) = 3.15, p = .114 
R2 = .61    QW(5) = 42.50, p < .001 
 
Continent:      
   Africa 
   Asia 
   Europe 
   North America 
















-2.98   0.02 
-1.80   -0.13 
-1.34   0.66 
-0.94   0.48 
-1.93   0.20 
F(4, 7) = 1.30, p = .357 
R2 = .09   QW(7) = 168.64, p < .001 
 
Funding?:      
   Yes 







-0.97   -0.14 
-2.91   -0.005 
F(1, 10) = 1.91, p = .196 
R2 = .08     QW(10) = 234.82, p < .001 
Note: N = total sample size. k = number of studies. d+ = average effect size. dL and dU = lower and upper confidence limits for d+. F = F-statistic for testing 
the significance of the moderator. R2 = proportion of variance accounted for by the moderator. QW = statistic for testing the model misspecification.  
a ‘Q-FISH’ (Quantitative Fluorescence In Situ Hybridization), ‘TAGGG Telomere Length Assay Kit’, and ‘Southern blot analysis of terminal restriction 
fragment lengths’. b ‘Oesophageal mucosa’. 
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Table 6. Results of the mixed-effects meta-regressions for continuous moderators on the effect sizes. 
 k Min. Max. Mean bj t p QE p R2 
    Substantive variables           
Year 12 2011 2019 2016 -0.014 -0.23 .821 237.68 < .001 0 
Total mean age 12 34.2 74.8 50.5 0.013 1.02 .330 197.38 < .001 .004 
Case mean age 11 26.2 74.5 47.4 0.010 0.81 .436 176.60 < .001 0 
Control mean age 12 33.3 75.1 55.7 0.006 0.48 .643 213.38 < .001 0 
Total SD of age 10 2.9 21.9 9.6 -0.040 -0.97 .358 189.80 < .001 .006 
Case SD of age 9 0.7 10.8 6.9 -0.046 -0.56 .593 193.22 < .001 0 
Control SD of age 10 0.6 11.2 6.7 -0.079 -1.12 .297 207.12 < .001 .01 
Total percent male 11 0 100 61.5 -0.006 -1.06 .315 184.03 < .001 .03 
Case percent male 11 0 100 66.1 -0.004 -0.84 .425 190.74 < .001 0 
Control percent male 12 0 100 56.1 -0.007 -1.34 .210 186.57 < .001 .08 
   Methodological 
variables 
          
Total sample size 12 49 1,880 600 0.0007 3.34 .007 105.28 < .001 .54 
Mean age differencea 11 -42.1 10.7 -7.7 0.005 0.45 .662 230.31 < .001 0 
SD of age differenceb 9 -1.1 1.04 -0.2 0.094 0.23 .822 186.30 < .001 0 
Percent male differencec 11 0 50 9.0 0.012 0.91 .384 200.70 < .001 0 
NOS Total scored 12 1 6 4.6 0.161 1.26 .237 230.42 < .001 .07 
Note: k = Number of studies. Min. and Max. = Minimum and Maximum values of the moderator variable. bj =Regression coefficient of the moderator. t = Statistic for testing the significance of the 
moderator. QE = statistic for testing the model misspecification. R2 =Proportion of variance accounted for by the moderator. In boldface is highlighted the moderator that reached statistical 
significance. 
a Mean age difference = Mean age of cases minus mean age of controls. 
 b SD of age difference = Age SD of cases minus age SD of controls.  
c Percent male difference = Percent male of cases minus percent male of controls.  
d Range of NOS total score: 0 – 9. 
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Figure 1. Flow chart of the Meta-Analysis of Telomere length and Substance Use Disorders. Adapted 
from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.  
doi:10.1371/journal.pone.0066227.g001 
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Figure 2. Forest plot of the standardized mean differences comparing average telomere length of 
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Figure 3. Funnel plot of the 12 standardized mean differences comparing average telomere length 
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NOS: Newcastle-Otawa Scale for case-control studies. NOS-S: Selection; NOS-C: 
Comparability; and NOS-E: Exposure. 
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